Thomas T Warner

List of Publications by Year
in descending order

219	13,383	18482 62	26613 107
papers	citations	h-index	g-index

225	225	225	14434
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neuroimaging correlates of brain injury in Wilsonâ€™s disease: a multimodal, whole-brain MRI study. Brain, 2022, 145, 263-275.	7.6	16
2	Neuropsychiatric Features of Punding and Hobbyism in Parkinson's Disease. Movement Disorders Clinical Practice, 2022, 9, 82-86.	1.5	2
3	REM Sleep Behavior Disorder and Visual Hallucinations in a Pathologically Confirmed Case of Corticobasal Degeneration. Movement Disorders Clinical Practice, 2022, 9, 383-385.	1.5	1
4	The faecal metabolome and mycobiome in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 95, 65-69.	2.2	11
5	Pathological Relevance of Post-Translationally Modified Alpha-Synuclein (pSer87, pSer129, nTyr39) in Idiopathic Parkinsonâ€™s Disease and Multiple System Atrophy. Cells, 2022, 11, 906.	4.1	14
6	Elevated 4Râ€‰tau in astrocytes from asymptomatic carriers of the MAPT 10+16 intronic mutation. Journal of Cellular and Molecular Medicine, 2022, 26, 1327-1331.	3.6	6
7	Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver. The Lancet Gastroenterology and Hepatology, 2022, 7, 560-575.	8.1	18
8	187â€… Variation in training: Results from a survey of UK neurology trainees. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A66.4-A66.	1.9	0
9	109â€… The ABN Acute Neurology Boot Camp: Pre- and post-course feedback for the inaugural event. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A45.2-A45.	1.9	0
10	Somatic copy number variant mutations in alpha-synuclein and genome-wide in brains of synucleinopathy cases. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A4.2-A4.	1.9	0
11	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. Movement Disorders, 2021, 36, 632-641.	3.9	3
12	Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinsonâ€™s disease dementia. Neuropathology and Applied Neurobiology, 2021, 47, 143-156.	3.2	19
13	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. Movement Disorders, 2021, 36, 503-508.	3.9	15
14	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology, The, 2021, 20, 107-116.	10.2	62
15	Hypothalamic Î±-synuclein and its relation to autonomic symptoms and neuroendocrine abnormalities in Parkinson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 182, 223-233.	1.8	2
16	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
17	Saccadic Bradykinesia in Parkinson's Disease: Preliminary Observations. Movement Disorders, 2021, 36, 1729-1731.	3.9	4
18	Identification of multiple system atrophy mimicking Parkinsonâ€™s disease or progressive supranuclear palsy. Brain, 2021, 144, 1138-1151.	7.6	24

#	Article	IF	Citations
19	Biallelic variants in TSPOAP1, encoding the active-zone protein RIMBP1, cause autosomal recessive dystonia. Journal of Clinical Investigation, 2021, 131, .	8.2	18
20	MIR-NATs repress MAPT translation and aid proteostasis in neurodegeneration. Nature, 2021, 594, 117-123.	27.8	29
21	Final Exon Frameshift Biallelic PTPN23 Variants Are Associated with Microcephalic Complex Hereditary Spastic Paraplegia. Brain Sciences, 2021, 11, 614.	2.3	5
22	Faster disease progression in Parkinsonâ€™s disease with type 2 diabetes is not associated with increased Î±â€synuclein, tau, amyloidâ€Î² or vascular pathology. Neuropathology and Applied Neurobiology, 2021, 47, 1080-1091.	3.2	14
23	Abrogation of LRRK2 dependent Rab10 phosphorylation with TLR4 activation and alterations in evoked cytokine release in immune cells. Neurochemistry International, 2021, 147, 105070.	3.8	18
24	Wilsonâ€™s disease: update on pathogenesis, biomarkers and treatments. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1053-1061.	1.9	44
25	Development of parkinsonism after long-standing cervical dystonia â€“ A cohort. Journal of the Neurological Sciences, 2021, 427, 117477.	0.6	10
26	MOBP and HIP1 in multiple system atrophy: New Î±â€synuclein partners in glial cytoplasmic inclusions implicated in the disease pathogenesis. Neuropathology and Applied Neurobiology, 2021, 47, 640-652.	3.2	11
27	The prevalence of impulsive compulsive behaviors in patients treated with apomorphine infusion: a retrospective analysis. Arquivos De Neuro-Psiquiatria, 2021, , .	0.8	0
28	Assembly of Î±-synuclein and neurodegeneration in the central nervous system of heterozygousÂM83 mice following the peripheral administration of Î±-synuclein seeds. Acta Neuropathologica Communications, 2021, 9, 189.	5.2	10
29	Reply to â€˜Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study.â€™. Parkinsonism and Related Disorders, 2021, 93, 31-32.	2.2	1
30	White matter DNA methylation profiling reveals deregulation of HIP1, LMAN2, MOBP, and other loci in multiple system atrophy. Acta Neuropathologica, 2020, 139, 135-156.	7.7	42
31	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 377.	9.0	94
32	Early presentation of urinary retention in multiple system atrophy: can the disease begin in the sacral spinal cord?. Journal of Neurology, 2020, 267, 659-664.	3.6	28
33	Clinical and pathogenic themes in hereditary spastic paraplegia. Brain, 2020, 143, 2864-2866.	7.6	3
34	Hippocampal Î±-synuclein pathology correlates with memory impairment in multiple system atrophy. Brain, 2020, 143, 1798-1810.	7.6	31
35	Epigenomics and transcriptomics analyses of multiple system atrophy brain tissue supports a role for inflammatory processes in disease pathogenesis. Acta Neuropathologica Communications, 2020, 8, 71.	5.2	5
36	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. Acta Neuropathologica, 2020, 139, 717-734.	7.7	15

#	Article	IF	Citations
37	Liver transplantation for late-onset presentations of acute liver failure in Wilson's disease: The UK experience over 2 decades. JHEP Reports, 2020, 2, 100096.	4.9	6
38	Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches. Lancet Neurology, The, 2019, 18, 1136-1146.	10.2	171
39	Saccadic Direction Errors are Associated with Impulsive Compulsive Behaviours in Parkinsonâ€™s Disease Patients. Journal of Parkinson's Disease, 2019, 9, 625-630.	2.8	13
40	The genetic and clinicoâ€pathological profile of earlyâ€onset progressive supranuclear palsy. Movement Disorders, 2019, 34, 1307-1314.	3.9	16
41	Lower nucleus accumbens Î±-synuclein load and D3 receptor levels in Parkinson's disease with impulsive compulsive behaviours. Brain, 2019, 142, 3580-3591.	7.6	17
42	Colonic transit, high-resolution anorectal manometry and MRI defecography study of constipation in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 66, 195-201.	2.2	27
43	The long-term outcome of impulsive compulsive behaviours in Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1288-1289.	1.9	3
44	Training in neurology: lessons learnt. Practical Neurology, 2019, 19, 431-437.	1.1	2
45	The BRadykinesia Akinesia INcoordination (BRAIN) Tap Test: Capturing the Sequence Effect. Movement Disorders Clinical Practice, 2019, 6, 462-469.	1.5	23
46	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	5.3	26
47	Author response: Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology, 2019, 92, 925-926.	1.1	0
48	Neuropathological progression of clinical Parkinson disease subtypes. Nature Reviews Neurology, 2019, 15, 361-361.	10.1	4
49	Copy number variation of LINGO1 in familial dystonic tremor. Neurology: Genetics, 2019, 5, e307.	1.9	8
50	Review: Clinical, neuropathological and genetic features of Lewy body dementias. Neuropathology and Applied Neurobiology, 2019, 45, 635-654.	3.2	26
51	Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing. Acta Neuropathologica Communications, 2019, 7, 219.	5.2	35
52	Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 555-561.	1.9	23
53	Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. JAMA Neurology, 2019, 76, 470.	9.0	205
54	Neuropathology of Circadian Alterations in Parkinson Diseaseâ€”Reply. JAMA Neurology, 2019, 76, 115.	9.0	1

#	Article	IF	Citations
55	Clinical presentations of Wilson disease. Annals of Translational Medicine, 2019, 7, S60-S60.	1.7	37
56	Phenotypes, genotypes, and the management of paroxysmal movement disorders. Developmental Medicine and Child Neurology, 2018, 60, 559-565.	2.1	31
57	No evidence of iatrogenic human transmission in autopsy confirmed multiple system atrophy. Movement Disorders, 2018, 33, 1183-1184.	3.9	4
58	Xeroderma pigmentosum is a definite cause of Huntington's diseaseâ€like syndrome. Annals of Clinical and Translational Neurology, 2018, 5, 102-108.	3.7	12
59	Dopamine reuptake transporterâ€“singleâ€photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. Movement Disorders, 2018, 33, 478-482.	3.9	25
60	A Histologic Study of the Circadian System in Parkinson Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy. JAMA Neurology, 2018, 75, 1008.	9.0	51
61	Compulsive sexual behaviour in Parkinsonâ€™s disease is associated with higher doses of levodopa. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1121-1123.	1.9	6
62	Dystonia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 159, 229-236.	1.8	6
63	Reply to: Youngâ€onset multiple system atrophy. Movement Disorders, 2018, 33, 1975-1976.	3.9	1
64	Delineating cerebellar mechanisms in DYT11 myoclonusâ€dystonia. Movement Disorders, 2018, 33, 1956-1961.	3.9	7
65	Youngâ€onset multiple system atrophy: Clinical and pathological features. Movement Disorders, 2018, 33, 1099-1107.	3.9	30
66	Autonomic Dysfunction in Parkinson's Disease: The Hidden Game Changer?. Movement Disorders, 2018, 33, 1028-1028.	3.9	3
67	Sensitivity and Specificity of the ECAS in Parkinsonâ€™s Disease and Progressive Supranuclear Palsy. Parkinson's Disease, 2018, 2018, 1-8.	1.1	11
68	Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinsonâ€™s disease brains with Lewy body pathology. Brain Research, 2018, 1701, 75-84.	2.2	25
69	Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype. Annals of Neurology, 2018, 84, 485-496.	5.3	37
70	The Outcome of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Retrospective Postmortem Study. Movement Disorders Clinical Practice, 2018, 5, 519-522.	1.5	14
71	Association between diabetes and subsequent Parkinson disease. Neurology, 2018, 91, e139-e142.	1.1	171
72	Neuroendocrine abnormalities in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 176-185.	1.9	70

#	Article	IF	Citations
73	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Parkinsonism and Related Disorders, 2017, 37, 65-71.	2.2	34
74	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	10.2	248
75	Iatrogenic B12-deficient peripheral neuropathy following nitrous oxide administration for functional tonic leg spasm: A case report. Clinical Neurology and Neurosurgery, 2017, 160, 108-110.	1.4	3
76	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1664-1675.	13.7	527
77	The neuropsychological profile of Othello syndrome in Parkinson's disease. Cortex, 2017, 96, 158-160.	2.4	8
78	Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. JAMA Neurology, 2017, 74, 970.	9.0	162
79	Dystonia. British Medical Bulletin, 2017, 123, 91-102.	6.9	4
80	A Retrospective Evaluation of the Frequency of Impulsive Compulsive Behaviors in Parkinson's Disease Patients Treated with Continuous Waking Day Apomorphine Pumps. Movement Disorders Clinical Practice, 2017, 4, 323-328.	1.5	33
81	Hypothalamic Î±-synuclein and its relation to weight loss and autonomic symptoms in Parkinson's disease. Movement Disorders, 2017, 32, 296-298.	3.9	22
82	Review: Induced pluripotent stem cell models of frontotemporal dementia. Neuropathology and Applied Neurobiology, 2016, 42, 497-520.	3.2	8
83	Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes. Movement Disorders Clinical Practice, 2016, 3, 382-388.	1.5	5
84	<scp>N</scp>omenclature of genetic movement disorders: <scp>R</scp>ecommendations of the international <scp>P</scp>arkinson and movement disorder society task force. Movement Disorders, 2016, 31, 436-457.	3.9	228
85	MSAâ€€ or SCA 17? A clinicopathological case update. Movement Disorders, 2016, 31, 1582-1584.	3.9	11
86	Reply letter to Jinnah â€œLocus pocusâ€•and Albanese â€œComplex dystonia is not a category in the new 2013 consensus classificationâ€• Necessary evolution, no magic!. Movement Disorders, 2016, 31, 1760-1762.	3.9	1
87	Clinical manifestations of intermediate allele carriers in Huntington disease. Neurology, 2016, 87, 571-578.	1.1	37
88	Genetic and phenotypic characterization of complex hereditary spastic paraplegia. Brain, 2016, 139, 1904-1918.	7.6	170
89	Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain, 2016, 139, 3237-3252.	7.6	107
90	DEEP PHENOTYPING OF THE G2019S LRRK2 MUTATION IN PARKINSON'S DISEASE: UCL COHORT. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.16-e1.	1.9	0

#	Article	IF	Citations
91	The impact of oculomotor functioning on neuropsychological performance in Huntington disease. Journal of Clinical and Experimental Neuropsychology, 2016, 38, 217-226.	1.3	3
92	Strategies for treatment of dystonia. Journal of Neural Transmission, 2016, 123, 251-258.	2.8	31
93	A Metabolic Study of Huntingtonâ€™s Disease. PLoS ONE, 2016, 11, e0146480.	2.5	41
94	Analysis of White Adipose Tissue Gene Expression Reveals CREB1 Pathway Altered in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2015, 4, 371-382.	1.9	11
95	A large Indian family with rearrangement of chromosome 4p16 and 3p26.3 and divergent clinical presentations. BMC Medical Genetics, 2015, 16, 104.	2.1	5
96	Late Emergence of Parkinsonian Phenotype and Abnormal Dopamine Transporter Scan in Choreaâ€Acanthocytosis. Movement Disorders Clinical Practice, 2015, 2, 182-186.	1.5	4
97	Systematic review and metaâ€analysis of salivary protein concentration in <scp>P</scp>arkinson's disease. Movement Disorders, 2015, 30, 1971-1972.	3.9	2
98	Effects of Age and Cognition on a Cross-Cultural Paediatric Adaptation of the Sniffin' Sticks Identification Test. PLoS ONE, 2015, 10, e0131641.	2.5	16
99	A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntingtonâ€™s Disease. PLoS ONE, 2015, 10, e0138848.	2.5	22
100	A partially inactivating mutation in the sodium-dependent lysophosphatidylcholine transporter MFSD2A causes a non-lethal microcephaly syndrome. Nature Genetics, 2015, 47, 814-817.	21.4	108
101	Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Human Molecular Genetics, 2015, 24, 5260-5269.	2.9	116
102	Concomitant fragile X-associated tremor ataxia syndrome and Parkinson's disease: a clinicopathological report of two cases: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 934-936.	1.9	20
103	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1240-1247.	1.9	196
104	Elevated salivary protein in Parkinson's disease and salivary DJ-1 as aÂpotential marker of disease severity. Parkinsonism and Related Disorders, 2015, 21, 1251-1255.	2.2	41
105	In a Rush to Decide: Deep Brain Stimulation and Dopamine Agonist Therapy in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 579-583.	2.8	9
106	Perceptual decision-making in patients with Parkinsonâ€™s disease. Journal of Psychopharmacology, 2014, 28, 1149-1154.	4.0	22
107	SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype. Journal of Neurology, 2014, 261, 2296-2304.	3.6	59
108	Nonmotor symptoms and focal cervical dystonia: Observations from 102 patients. Basal Ganglia, 2014, 4, 117-120.	0.3	37

#	Article	IF	Citations
109	DRD1 rare variants associated with tardive-like dystonia: A pilot pathway sequencing study in dystonia. Parkinsonism and Related Disorders, 2014, 20, 782-785.	2.2	7
110	Plasma melatonin is reduced in Huntington's disease. Movement Disorders, 2014, 29, 1511-1515.	3.9	81
111	Do Parkinson's Disease Patients Have Deficits in Sequential Sampling Tasks?. Movement Disorders Clinical Practice, 2014, 1, 325-328.	1.5	1
112	Late onset ataxia: MSAâ€€ or SCA 17? A gene penetrance dilemma. Movement Disorders, 2014, 29, 36-38.	3.9	26
113	Dystonia rating scales: Critique and recommendations. Movement Disorders, 2013, 28, 874-883.	3.9	150
114	PRRT2-related disorders: further PKD and ICCA cases and review of the literature. Journal of Neurology, 2013, 260, 1234-1244.	3.6	63
115	Perrault Syndrome Is Caused by Recessive Mutations in CLPP, Encoding a Mitochondrial ATP-Dependent Chambered Protease. American Journal of Human Genetics, 2013, 92, 605-613.	6.2	186
116	Emerging common molecular pathways for primary dystonia. Movement Disorders, 2013, 28, 968-981.	3.9	40
117	SGCE mutations cause psychiatric disorders: clinical and genetic characterization. Brain, 2013, 136, 294-303.	7.6	91
118	ARE PSYCHIATRIC SYMPTOMS A CORE PHENOTYPE OF MYOCLONUS DYSTONIA SYNDROME CAUSED BY SGCE MUTATIONS?. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e1-e1.	1.9	0
119	Recent Advances in the Molecular Pathogenesis of Dystonia-Plus Syndromes and Heredodegenerative Dystonias. Current Neuropharmacology, 2013, 11, 30-40.	2.9	4
120	A Critical Evaluation of Inflammatory Markers in Huntington's Disease Plasma. Journal of Huntington's Disease, 2013, 2, 125-134.	1.9	25
121	A Systematic Evaluation of Integration Free Reprogramming Methods for Deriving Clinically Relevant Patient Specific Induced Pluripotent Stem (iPS) Cells. PLoS ONE, 2013, 8, e81622.	2.5	57
122	1624â€...Myoclonus dystonia: a clinical and genetic description: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.146-e1.	1.9	0
123	Paroxysmal exerciseâ€induced dyskinesia of the hands. Movement Disorders, 2012, 27, 1579-1580.	3.9	6
124	What sample sizes for reliability and validity studies in neurology?. Journal of Neurology, 2012, 259, 2681-2694.	3.6	140
125	Screening for mutations in the phosphatidylinositol 4-kinase 2-alpha gene in autosomal recessive hereditary spastic paraplegia. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 148-149.	2.1	6
126	The Trail Making Test in prodromal Huntington disease: Contributions of disease progression to test performance. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 567-579.	1.3	52

#	Article	IF	Citations
127	CSN complex controls the stability of selected synaptic proteins via a torsinA-dependent process. EMBO Journal, 2011, 30, 181-193.	7.8	39
128	Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurology, The, 2011, 10, 1074-1085.	10.2	178
129	An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers. Movement Disorders, 2011, 26, 877-884.	3.9	34
130	Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain, 2011, 134, 137-142.	7.6	118
131	Longitudinal change in regional brain volumes in prodromal Huntington disease. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 405-410.	1.9	220
132	Estimating Premorbid IQ in the Prodromal Phase of a Neurodegenerative Disease. Clinical Neuropsychologist, 2011, 25, 757-777.	2.3	15
133	TorsinA and DYT1 dystonia: a synaptopathy?. Biochemical Society Transactions, 2010, 38, 452-456.	3.4	17
134	Self-paced timing detects and tracks change in prodromal Huntington disease.. Neuropsychology, 2010, 24, 435-442.	1.3	79
135	Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiology of Disease, 2010, 40, 531-543.	4.4	74
136	Cerebral cortex structure in prodromal Huntington disease. Neurobiology of Disease, 2010, 40, 544-554.	4.4	142
137	CAGâ€repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 397-408.	1.7	289
138	Challenges assessing clinical endpoints in early Huntington disease. Movement Disorders, 2010, 25, 2595-2603.	3.9	65
139	The role of torsinA in dystonia. European Journal of Neurology, 2010, 17, 81-87.	3.3	48
140	Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Research Bulletin, 2010, 82, 201-207.	3.0	214
141	The Genetics and Pathogenesis of Dystonia. Blue Books of Neurology, 2010, 34, 457-473.	0.1	0
142	Loss of phosphatidylinositol 4-kinase 2Î± activity causes late onset degeneration of spinal cord axons. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11535-11539.	7.1	77
143	Motor abnormalities in premanifest persons with Huntington's disease: The PREDICTâ€HD study. Movement Disorders, 2009, 24, 1763-1772.	3.9	128
144	Four novel SPG3A/atlastin mutations identified in autosomal dominant hereditary spastic paraplegia kindreds with intraâ€familial variability in age of onset and complex phenotype. Clinical Genetics, 2009, 75, 485-489.	2.0	21

#	Article	IF	Citations
145	TorsinA and dystonia: from nuclear envelope to synapse. Journal of Neurochemistry, 2009, 109, 1596-1609.	3.9	58
146	Characterization of a novel TYMP splice site mutation associated with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Neuromuscular Disorders, 2009, 19, 151-154.	0.6	29
147	Sequence Alterations within CYP7B1 Implicate Defective Cholesterol Homeostasis in Motor-Neuron Degeneration. American Journal of Human Genetics, 2008, 82, 510-515.	6.2	171
148	Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurology, The, 2008, 7, 1127-1138.	10.2	481
149	The Cervical Dystonia Impact Profile (CDIP-58): Can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?. Health and Quality of Life Outcomes, 2008, 6, 58.	2.4	19
150	The Dystonia-associated Protein TorsinA Modulates Synaptic Vesicle Recycling. Journal of Biological Chemistry, 2008, 283, 7568-7579.	3.4	100
151	Psychiatric Symptoms in Huntingtonâ€™s Disease before Diagnosis: The Predict-HD Study. Biological Psychiatry, 2007, 62, 1341-1346.	1.3	363
152	Evidence-based guidelines for using the Short Form 36 in cervical dystonia. Movement Disorders, 2007, 22, 122-127.	3.9	18
153	Myoclonusâ€“dystonia syndrome with severe depression is caused by an exon-skipping mutation in the É›-sarcoglycan gene. Movement Disorders, 2007, 22, 1173-1175.	3.9	41
154	Spastin and microtubules: Functions in health and disease. Journal of Neuroscience Research, 2007, 85, 2778-2782.	2.9	70
155	CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology, 2006, 67, 2230-2232.	1.1	49
156	Increased rate of whole-brain atrophy over 6 months in early Huntington disease. Neurology, 2006, 67, 694-696.	1.1	45
157	Human spastin has multiple microtubule-related functions. Journal of Neurochemistry, 2005, 95, 1411-1420.	3.9	54
158	Mutant torsinA, which causes early-onset primary torsion dystonia, is redistributed to membranous structures enriched in vesicular monoamine transporter in cultured human SH-SY5Y cells. Movement Disorders, 2005, 20, 432-440.	3.9	48
159	A novel NIPA1 mutation associated with a pure form of autosomal dominant hereditary spastic paraplegia. Neurogenetics, 2005, 6, 79-84.	1.4	51
160	High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study. Neurology, 2005, 64, 1655-1656.	1.1	87
161	A new locus for autosomal recessive complicated hereditary spastic paraplegia (SPG26) maps to chromosome 12p11.1-12q14. Journal of Medical Genetics, 2005, 42, 80-82.	3.2	43
162	Comparison of Cumulus Parameterizations and Entrainment Using Domain-Mean Wind Divergence in a Regional Model. Journals of the Atmospheric Sciences, 2004, 61, 1284-1295.	1.7	16

#	Article	IF	Citations
163	A clinical, genetic and biochemical study of SPG7 mutations in hereditary spastic paraplegia. Brain, 2004, 127, 973-980.	7.6	77
164	Capturing the true burden of dystonia on patients. Neurology, 2004, 63, 1629-1633.	1.1	94
165	Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nature Genetics, 2004, 36, 271-276.	21.4	349
166	A clinical, genetic and candidate gene study of Silver syndrome, a complicated form of hereditary spastic paraplegia. Journal of Neurology, 2004, 251, 1068-74.	3.6	11
167	A novel RAB7 mutation associated with ulceroâ€mutilating neuropathy. Annals of Neurology, 2004, 56, 586-590.	5.3	112
168	Patient-based outcomes of cervical dystonia: A review of rating scales. Movement Disorders, 2004, 19, 1054-1059.	3.9	38
169	Screening of patients with hereditary spastic paraplegia reveals seven novel mutations in theSPG4 (Spastin) gene. Human Mutation, 2003, 21, 170-170.	2.5	31
170	Analysis of the ?-sarcoglycan gene in familial and sporadic myoclonus-dystonia: Evidence for genetic heterogeneity. Movement Disorders, 2003, 18, 1047-1051.	3.9	58
171	Genetic and environmental factors in the cause of Parkinson's disease. Annals of Neurology, 2003, 53, S16-S25.	5.3	327
172	SPG3A mutation screening in English families with early onset autosomal dominant hereditary spastic paraplegia. Journal of the Neurological Sciences, 2003, 216, 43-45.	0.6	27
173	Diurnal Patterns of Rainfall in Northwestern South America. Part II: Model Simulations. Monthly Weather Review, 2003, 131, 813-829.	1.4	70
174	Diurnal Patterns of Rainfall in Northwestern South America. Part III: Diurnal Gravity Waves and Nocturnal Convection Offshore. Monthly Weather Review, 2003, 131, 830-844.	1.4	243
175	Diurnal Patterns of Rainfall in Northwestern South America. Part I: Observations and Context. Monthly Weather Review, 2003, 131, 799-812.	1.4	140
176	A clinical and genetic study of SPG5A linked autosomal recessive hereditary spastic paraplegia. Neurology, 2003, 61, 235-238.	1.1	32
177	No association with common Caucasian genotypes in exons 8, 13 and 14 of the human cytoplasmic dynein heavy chain gene (DNCHC1) and familial motor neuron disorders. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 150-157.	1.2	26
178	Creatine therapy for Huntingtonâ€™s disease: Clinical and MRS findings in a 1-year pilot study. Neurology, 2003, 61, 141-142.	1.1	92
179	What are the determinants of quality of life in people with cervical dystonia?. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 608-614.	1.9	169
180	A polymorphism in the dopamine receptor DRD5 is associated with blepharospasm. Neurology, 2002, 58, 124-126.	1.1	69

#	Article	IF	Citations
181	Basic genetics for the clinical neurologist. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 5ii-11.	1.9	0
182	Three novel spastin (SPG4) mutations in families with autosomal dominant hereditary spastic paraplegia. Journal of the Neurological Sciences, 2002, 201, 65-69.	0.6	16
183	Genetic and clinical heterogeneity in paroxysmal kinesigenic dyskinesia: Evidence for a third EKD gene. Movement Disorders, 2002, 17, 717-725.	3.9	85
184	Impact of cervical dystonia on quality of life. Movement Disorders, 2002, 17, 838-841.	3.9	110
185	The Silver Syndrome Variant of Hereditary Spastic Paraplegia Maps to Chromosome 11q12-q14, with Evidence for Genetic Heterogeneity within This Subtype. American Journal of Human Genetics, 2001, 69, 209-215.	6.2	81
186	A large family with hereditary spastic paraparesis due to a frame shift mutation of the spastin (SPG4) gene: association with multiple sclerosis in two affected siblings and epilepsy in other affected family members. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 788-791.	1.9	41
187	Dystonia: an update on genetics and treatment. Current Opinion in Neurology, 2001, 14, 471-475.	3.6	8
188	Silver syndrome is not linked to any of the previously established autosomal dominant hereditary spastic paraplegia loci. American Journal of Medical Genetics Part A, 2001, 102, 68-72.	2.4	11
189	Cervical dystonia is associated with a polymorphism in the dopamine (D5) receptor gene. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 262-264.	1.9	50
190	Friedreich's ataxia presenting as an isolated spastic paraparesis. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 709-709.	1.9	4
191	Nested-Model Simulation of Moist Convection: The Impact of Coarse-Grid Parameterized Convection on Fine-Grid Resolved Convection. Monthly Weather Review, 2000, 128, 2211-2231.	1.4	81
192	Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Annals of Neurology, 2000, 48, 72-76.	5.3	244
193	Churgâ€“Strauss syndrome presenting with visual loss. Rheumatology, 2000, 39, 1433-1434.	1.9	13
194	Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Human Molecular Genetics, 2000, 9, 2683-2689.	2.9	182
195	Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Annals of Neurology, 2000, 48, 72-76.	5.3	1
196	Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Annals of Neurology, 2000, 48, 72-6.	5.3	92
197	Detailed haplotype analysis in Ashkenazi Jewish and non-Jewish British dystonic patients carrying the GAG deletion in the DYT1 gene: evidence for a limited number of founder mutations. Annals of Human Genetics, 1999, 63, 1-8.	0.8	23
198	The genetics of Parkinson's disease and parkinsonian syndromes. Journal of Neurology, 1998, 245, 625-633.	3.6	10

#	Article	IF	Citations
199	The molecular genetics of the dystonias. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 427-429.	1.9	11
200	The role of the alpha -synuclein gene mutation in patients with sporadic Parkinson's disease in the United Kingdom. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 378-379.	1.9	28
201	The role of DYT1 in primary torsion dystonia in Europe. Brain, 1998, 121, 2335-2339.	7.6	177
202	The dystonias.. Journal of Medical Genetics, 1998, 35, 314-318.	3.2	10
203	A Tutorial on Lateral Boundary Conditions as a Basic and Potentially Serious Limitation to Regional Numerical Weather Prediction. Bulletin of the American Meteorological Society, 1997, 78, 2599-2617.	3.3	375
204	Genetic counselling in mitochondrial diseases. Current Opinion in Neurology, 1997, 10, 408-412.	3.6	8
205	Complex I function in familial and sporadic dystonia. Annals of Neurology, 1997, 41, 556-559.	5.3	78
206	Exclusion of the DYT1 locus in familial torticollis. Annals of Neurology, 1996, 40, 681-684.	5.3	74
207	Encephalomyelitis in primary hypogammaglobulinaemia. Brain, 1996, 119, 1-15.	7.6	150
208	Overactive prefrontal and underactive motor cortical areas in idiopathic dystonia. Annals of Neurology, 1995, 37, 363-372.	5.3	299
209	A clinical and molecular genetic study of dentatorubropallidoluysian atrophy in four european families. Annals of Neurology, 1995, 37, 452-459.	5.3	78
210	Central alveolar hypoventilation associated with paraneoplastic brain-stem encephalitis and anti-Hu antibodies. Journal of Neurology, 1994, 241, 561-566.	3.6	19
211	Autosomal-dominant dentatorubropallidoluysian atrophy in the United Kingdom. Movement Disorders, 1994, 9, 289-296.	3.9	53
212	DRPLA in Europe. Nature Genetics, 1994, 6, 225-225.	21.4	53
213	Linkage analysis with chromosome 9 markers in hereditary essential tremor. Movement Disorders, 1993, 8, 374-376.	3.9	38
214	Hypokalaemia mimicking Guillain-Barre syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 1134-1135.	1.9	8
215	Linkage analysis in British and French families with idiopathic torsion dystonia. Brain, 1993, 116, 739-744.	7.6	33
216	Reactivation of tuberculous lymphadenitis during pregnancy. Journal of Infection, 1992, 24, 181-184.	3.3	3

#	Article	IF	Citations
217	Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11 -epoxide. Epilepsy Research, 1992, 11, 147-150.	1.6	116
218	Chromosomes from the epithelium of plucked human telogen hairs. Human Genetics, 1983, 63, 315-316.	3.8	12
219	Neuroimaging Correlates of Cognitive Deficits in Wilson's Disease. Movement Disorders, 0, , .	3.9	7